| Molecular Formula | C16H20N2 |
| Molar Mass | 240.34 |
| Density | 1.086±0.06 g/cm3(Predicted) |
| Melting Point | 104.4-105.0℃ |
| Boling Point | 418.7±40.0 °C(Predicted) |
| Solubility | DMSO: >10mg/mL |
| Appearance | solid |
| Color | off-white to gray-pink |
| pKa | 5.99±0.11(Predicted) |
| Storage Condition | -20°C |
| In vitro study | JSH-23 inhibited LPS-induced NF-κB p65 nuclear transport without affecting the degradation of IκB Alpha. JSH-23 inhibited LPS-induced apoptotic chromatin concentration, but showed no significant toxic effect on RAW 100 cells at <264.7 μm. JSH-23 also reduced NO production and neuronal migration in LPS-activated culture medium from mouse cerebellar primary cultures. In addition, JSH-23 increased the cytotoxicity of cisplatin compounds in ovarian cancer cells with CI values ranging from 0.35 to 0.85. |
| In vivo study | In diabetic rats, JSH-23(3 mg/kg) significantly reversed nerve conduction and improved neural blood flow deficits by reducing neuroinflammation and enhancing antioxidant defense. |
| Risk Codes | R22 - Harmful if swallowed R41 - Risk of serious damage to eyes R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye / face protection. S60 - This material and its container must be disposed of as hazardous waste. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
| UN IDs | UN 3077 9 / PGIII |
| WGK Germany | 3 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.161 ml | 20.804 ml | 41.608 ml |
| 5 mM | 0.832 ml | 4.161 ml | 8.322 ml |
| 10 mM | 0.416 ml | 2.08 ml | 4.161 ml |
| 5 mM | 0.083 ml | 0.416 ml | 0.832 ml |
| biological activity | JSH-23 inhibits the transcriptional activity of NF-κB, IC50 is 7.1 μM. |
| in vitro study | JSH-23 inhibit LPS-induced NF-κB p65 nuclear transport without affecting IκBα degradation. JSH-23 inhibited LPS-induced apoptotic chromatin concentration, but did not show significant toxic effect on RAW 264.7 cells at <100 μM. JSH-23 also reduced LPS-activated NO production and neuronal migration in culture medium from mouse cerebellum primary culture. In addition, CI values ranged from 0.35 to 0.85 JSH-23 increasing the cytotoxicity of cisplatin compounds in ovarian cancer cells. |
| in vivo study | in diabetic rats, JSH-23(3 mg/kg) significantly reverses nerve conduction and improves nerve blood flow deficiency by reducing nerve inflammation and improving antioxidant defense. |
| target | NF-κB 7.1 μ m (IC 50 , in RAW 264.7 cells) |